Pituitary apoplexy following adenoviral vector-based COVID-19 vaccination

Pituitary apoplexy (PA) may complicate the course of coronavirus disease 2019 (COVID-19), posing a potential threat to life. Among vaccines designed to prevent COVID-19, there are those adenoviral vector-based, such as Vaxzevria® (formerly COVID-19 Vaccine AstraZeneca). The product insert states tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Roncati, Luca, Manenti, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Hemorrhagic Stroke Association. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. 2023
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017089/
https://www.ncbi.nlm.nih.gov/pubmed/35464129
http://dx.doi.org/10.1016/j.hest.2022.04.002
_version_ 1784688703724060672
author Roncati, Luca
Manenti, Antonio
author_facet Roncati, Luca
Manenti, Antonio
author_sort Roncati, Luca
collection PubMed
description Pituitary apoplexy (PA) may complicate the course of coronavirus disease 2019 (COVID-19), posing a potential threat to life. Among vaccines designed to prevent COVID-19, there are those adenoviral vector-based, such as Vaxzevria® (formerly COVID-19 Vaccine AstraZeneca). The product insert states that it can cause very rare coagulation disorders, in particular thrombosis with thrombocytopenia syndrome in some cases accompanied by bleeding, cerebrovascular venous or sinus thrombosis, and thrombocytopenia, including immune thrombocytopenia, also associated with bleeding. Here, we report the onset of PA after Vaxzevria® in a 28-year-old healthy Caucasian female, who experienced long-lasting tension-type headache, hyperprolactinemia and menstrual changes, without thrombocytopenia or thrombosis.
format Online
Article
Text
id pubmed-9017089
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher International Hemorrhagic Stroke Association. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.
record_format MEDLINE/PubMed
spelling pubmed-90170892022-04-19 Pituitary apoplexy following adenoviral vector-based COVID-19 vaccination Roncati, Luca Manenti, Antonio Brain Hemorrhages Clinical Research Pituitary apoplexy (PA) may complicate the course of coronavirus disease 2019 (COVID-19), posing a potential threat to life. Among vaccines designed to prevent COVID-19, there are those adenoviral vector-based, such as Vaxzevria® (formerly COVID-19 Vaccine AstraZeneca). The product insert states that it can cause very rare coagulation disorders, in particular thrombosis with thrombocytopenia syndrome in some cases accompanied by bleeding, cerebrovascular venous or sinus thrombosis, and thrombocytopenia, including immune thrombocytopenia, also associated with bleeding. Here, we report the onset of PA after Vaxzevria® in a 28-year-old healthy Caucasian female, who experienced long-lasting tension-type headache, hyperprolactinemia and menstrual changes, without thrombocytopenia or thrombosis. International Hemorrhagic Stroke Association. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. 2023-03 2022-04-19 /pmc/articles/PMC9017089/ /pubmed/35464129 http://dx.doi.org/10.1016/j.hest.2022.04.002 Text en © 2022 International Hemorrhagic Stroke Association. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Clinical Research
Roncati, Luca
Manenti, Antonio
Pituitary apoplexy following adenoviral vector-based COVID-19 vaccination
title Pituitary apoplexy following adenoviral vector-based COVID-19 vaccination
title_full Pituitary apoplexy following adenoviral vector-based COVID-19 vaccination
title_fullStr Pituitary apoplexy following adenoviral vector-based COVID-19 vaccination
title_full_unstemmed Pituitary apoplexy following adenoviral vector-based COVID-19 vaccination
title_short Pituitary apoplexy following adenoviral vector-based COVID-19 vaccination
title_sort pituitary apoplexy following adenoviral vector-based covid-19 vaccination
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017089/
https://www.ncbi.nlm.nih.gov/pubmed/35464129
http://dx.doi.org/10.1016/j.hest.2022.04.002
work_keys_str_mv AT roncatiluca pituitaryapoplexyfollowingadenoviralvectorbasedcovid19vaccination
AT manentiantonio pituitaryapoplexyfollowingadenoviralvectorbasedcovid19vaccination

Ejemplares similares